Cardio-oncology/onco-cardiology

Clinical Cardiology

Volumn 33, Issue 12, 2010, Pages 733-737

  Hong, Robert A ^a   Iimura, Takeshi ^a   Sumida, Kenneth N ^a   Eager, Robert M ^a  

^a QUEEN S MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALKYLATING AGENT; ALPHA INTERFERON; ANGIOTENSIN RECEPTOR ANTAGONIST; ANTHRACYCLINE; ANTHRAQUINONE DERIVATIVE; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; BEVACIZUMAB; BLEOMYCIN; CYCLOPHOSPHAMIDE; CYTARABINE; DASATINIB; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DOXORUBICIN; EPIRUBICIN; ERLOTINIB; ETOPOSIDE; FLUOROURACIL; IMATINIB; INTERLEUKIN 2; LAPATINIB; LENALIDOMIDE; MITOXANTRONE; MONOCLONAL ANTIBODY; PROTEIN TYROSINE KINASE INHIBITOR; SUNITINIB; THALIDOMIDE; TRASTUZUMAB; VINBLASTINE; VORINOSTAT;

BREAST CANCER; CANCER CHEMOTHERAPY; CANCER PATIENT; CANCER RADIOTHERAPY; CARDIOLOGY; CARDIOMYOPATHY; CARDIOTOXICITY; CORONARY ARTERY DISEASE; HEART ARRHYTHMIA; HEART MUSCLE FIBROSIS; HEART MUSCLE ISCHEMIA; HUMAN; METASTASIS; ONCOLOGY; PERICARDITIS; REVIEW; SYSTOLIC DYSFUNCTION; THROMBOPHILIA;

ANTICOAGULANTS; ANTINEOPLASTIC AGENTS; CARDIOLOGY; CARDIOVASCULAR AGENTS; COOPERATIVE BEHAVIOR; HEART DISEASES; HEART FUNCTION TESTS; HUMANS; MEDICAL ONCOLOGY; PATIENT CARE TEAM; PREDICTIVE VALUE OF TESTS; RADIATION INJURIES; THROMBOPHILIA;

EID: 78650632464     PISSN: 01609289     EISSN: 19328737     Source Type: Journal    
DOI: 10.1002/clc.20823     Document Type: Review

References (58)

1. Yeh ETH, Bickford CL,. Cardiovascular complications of cancer therapy: incidence, pathogenesis, diagnosis, and management. J Am Coll Cardiol 2009; 53: 2231-2247.
2. Swain SM, Whaley FS, Ewer MS,. Congestive heart failure in patients treated with doxorubicin: a retrospective analysis of three trials. Cancer 2003; 97: 2869-2879.
3. Seidman A, Hudis C, Pierri MK, et al., Cardiac dysfunction in the trastuzumab clinical trials experience. J Clin Oncol 2002; 20: 1215-1221.
4. Giordano SH, Booser DJ, Murray JL, et al., A detailed evaluation of cardiac toxicity: a phase II study of doxorubicin and one- or three- hour- infusion paclitaxel in patients with metastatic breast cancer. Clin Cancer Res 2002; 8: 3360-3368.
5. van Dalen EC, Caron HN, Dickinson HO, et al., Cardioprotective interventions for cancer patients receiving anthracyclines. Cochrane Database Syst Rev 2005; CD003917. Accessed April 16, 2008.
6. Hensley ML, Hagerty KL, Kewalramani T, et al., American Society of Clinical Oncology 2008 clinical practice guideline update: use of chemotherapy and radiation therapy protectants. J Clin Oncol 2009; 27: 127-145.
7. van Dalen EC, van der Pal HJH, Bakker PJM, et al., Cumulative incidence and risk factors of mitoxantrone-induced cardiotoxicity in children: a systematic review. Eur J Cancer 2004; 40: 643-652.
8. Guglin M, Hartlage G, Reynolds C, et al., Trastuzumab-induced cardiomyopathy: not as benign as it looks? A retrospective study. J Card Fail 2009; 15: 651-657.
9. Ewer MS, Vooletich MT, Durand J, et al., Reversibility of trastuzumab-related cardiotoxicity: new insights based on clinical course and response to medical treatment. J Clin Oncol 2005; 23: 7820-7826.
10. Perez EA, Koehler M, Byrne J, et al., Cardiac safety of lapatinib: pooled analysis of 3689 patients enrolled in clinical trials. Mayo Clin Proc 2008; 83: 679-686.
11. Atallah E, Durand J, Kantarjian H, et al., Congestive heart failure is a rare event in patients receiving imatinib therapy. Blood 2007; 110: 1233-1237.
12. Khakoo AY, Kassiotis CM, Tannir N, et al., Heart failure associated with sunitinib malate: a multitargeted receptor tyrosine kinase inhibitor. Cancer 2008; 112: 2500-2508.
13. Chu TF, Rupnick MA, Kerkela R, et al., Cardiotoxicity associated with tyrosine kinase inhibitor sunitinib. Lancet 2007; 370: 2011-2019.
14. Kantarjian H, Cortes J, Kim D, et al., Phase 3 study of dasatinib 140 mg once daily versus 70 mg twice daily in patients with chronic myeloid leukemia in accelerated phase resistant or intolerant to imatinib: 15-month median follow-up. Blood 2009; 113: 6322-6329.
15. Gottdiener JS, Appelbaum FR, Ferrans VJ, et al., Cardiotoxicity associated with high-dose cyclophosphamide therapy. Arch Intern Med 1981; 141: 758-763.
16. Sonnenblick M, Rosin A,. Cardiotoxicity of interferon. A review of 44 cases. Chest 1991; 99: 557-561.
17. Miller KD, Chap LI, Holmes FA, et al., Randomized phase III trial of capecitabine compared with bevacizumab plus capecitabine in patients with previously treated metastatic breast cancer. J Clin Oncol 2005; 23: 792-799.
18. Van Cutsem E, Hoff PM, Blum JL, et al., Incidence of cardiotoxicity with the oral fluoropyrimidine capecitabine is typical of that reported with 5-fluorouracil. Ann Oncol 2002; 13: 484-485.
19. Ang C, Kornbluth M, Thirlwell MP, et al., Capecitabine-induced cardiotoxicity: case report and review of the literature. Curr Oncol 2010; 17: 59-63.
20. Rezkalla S, Kloner RA, Ensley J, et al., Continuous ambulatory ECG monitoring during fluorouracil therapy: a prospective study. J Clin Oncol 1989; 7: 509-514.
21. Tsibiribi P, Descotes J, Lombard-Bohas C, et al., Cardiotoxicity of 5-fluorouracil in 1350 patients with no prior history of heart disease. Bull Cancer 2006; 93: E27-E30.
22. Labianca R, Beretta G, Clerici M, et al., Cardiac toxicity of 5-fluorouracil: a study on 1083 patients. Tumori 1982; 68: 505-510.
23. Schwarzer S, Eber B, Greinix H, et al., Non-Q-wave myocardial infarction associated with bleomycin and etoposide chemotherapy. Eur Heart J 1991; 12: 748-750.
24. Yano S, Shimada K,. Vasospastic angina after chemotherapy by with carboplatin and etoposide in a patient with lung cancer. Jpn Circ J 1996; 60: 185-188.
25. Schecter JP, Jones SE, Jackson RA,. Myocardial infarction in a 27-year-old woman: possible complication of treatment with VP-16-213 (NSC-141540), mediastinal irradiation, or both. Cancer Chemother Rep 1975; 59: 887-888.
26. Durkin WJ, Pugh RP, Solomon J, et al., Treatment of advanced lymphomas with bleomycin (NSC-125066). Oncology 1976; 33: 140-145.
27. Swerdlow AJ, Higgins CD, Smith P, et al., Myocardial infarction mortality risk after treatment for Hodgkin disease: a collaborative British cohort study. J Natl Cancer Inst 2007; 99: 206-214.
28. Subar M, Muggia FM,. Apparent myocardial ischemia associated with vinblastine administration. Cancer Treat Rep 1986; 70: 690-691.
29. Scappaticci FA, Skillings JR, Holden SN, et al., Arterial thromboembolic events in patients with metastatic carcinoma treated with chemotherapy and bevacizumab. J Natl Cancer Inst 2007; 99: 1232-1239.
30. Escudier B, Eisen T, Stadler WM, et al., Sorafenib in advanced clear-cell renal-cell carcinoma. N Engl J Med 2007; 356: 125-134.
31. Arbuck SG, Strauss H, Rowinsky E, et al., A reassessment of cardiac toxicity associated with Taxol. J Natl Cancer Inst Monogr 1993; No. 15: 117-130.
32. Lee RE, Lotze MT, Skibber JM, et al., Cardiorespiratory effects of immunotherapy with interleukin-2. J Clin Oncol 1989; 7: 7-20.
33. Soignet SL, Frankel SR, Douer D, et al., United States multicenter study of arsenic trioxide in relapsed acute promyelocytic leukemia. J Clin Oncol 2001; 19: 3852-3860.
34. McLellan RA, Drobitch RK, Monshouwer M, et al., Fluoroquinolone antibiotics inhibit cytochrome P450-mediated microsomal drug metabolism in rat and human. Drug Metab Dispos 1996; 24: 1134-1138.
35. Fang J, Gorrod JW,. Metabolism, pharmacogenetics, and metabolic drug-drug interactions of antipsychotic drugs. Cell Mol Neurobiol 1999; 19: 491-510.
36. Reykdal S, Sham R, Kouides P,. Cytarabine-induced pericarditis: a case report and review of the literature of the cardio-pulmonary complications of cytarabine therapy. Leuk Res 1995; 19: 141-144.
37. Palumbo A, Rajkumar SV, Dimopoulos MA, et al., Prevention of thalidomide- and lenalidomide-associated thrombosis in myeloma. Leukemia 2008; 22: 414-423.
38. Moore MJ, Goldstein D, Hamm J, et al., Erlotinib plus gemcitabine compared with gemcitabine alone in patients with advanced pancreatic cancer: a phase III trial of the National Cancer Institute of Canada Clinical Trials Group. J Clin Oncol 2007; 25: 1960-1966.
39. Olsen EA, Kim YH, Kuzel TM, et al., Phase IIb multicenter trial of vorinostat in patients with persistent, progressive, or treatment refractory cutaneous T-cell lymphoma. J Clin Oncol 2007; 25: 3109-3115.
40. Brosius FC, Waller BF, Roberts WC,. Radiation heart disease. Analysis of 16 young (aged 15 to 33 years) necropsy patients who received over 3,500 rads to the heart. Am J Med 1981; 70: 519-530.
41. Veinot JP, Edwards WD,. Pathology of radiation-induced heart disease: a surgical and autopsy study of 27 cases. Hum Pathol 1996; 27: 766-773.
42. Carmel RJ, Kaplan HS,. Mantle irradiation in Hodgkin's disease. An analysis of technique, tumor eradication, and complications. Cancer 1976; 37: 2813-2825.
43. Heidenreich PA, Hancock SL, Vagelos RH, et al., Diastolic dysfunction after mediastinal irradiation. Am Heart J 2005; 150: 977-982.
44. Gyenes G, Fornander T, Carlens P, et al., Detection of radiation-induced myocardial damage by technetium-99m sestamibi scintigraphy. Eur J Nucl Med 1997; 24: 286-292.
45. Cuzick J, Stewart H, Rutqvist L, et al., Cause-specific mortality in long-term survivors of breast cancer who participated in trials of radiotherapy. J Clin Oncol 1994; 12: 447-453.
46. Hooning MJ, Botma A, Aleman BMP, et al., Long-term risk of cardiovascular disease in 10-year survivors of breast cancer. J Natl Cancer Inst 2007; 99: 365-375.
47. Keefe DL,. Trastuzumab-associated cardiotoxicity. Cancer 2002; 95: 1592-1600.
48. Schwartz RG, McKenzie WB, Alexander J, et al., Congestive heart failure and left ventricular dysfunction complicating doxorubicin therapy. Seven-year experience using serial radionuclide angiocardiography. Am J Med 1987; 82: 1109-1118.
49. Ganz WI, Sridhar KS, Ganz SS, et al., Review of tests for mon- itoring doxorubicin-induced cardiomyopathy. Oncology 1996; 53: 461-470.
50. van Dalen EC, van den Brug M, Caron HN, et al., Anthracycline-induced cardiotoxicity: comparison of recommendations for monitoring cardiac function during therapy in paediatric oncology trials. Eur J Cancer 2006; 42: 3199-3205.
51. Steinherz LJ, Graham T, Hurwitz R, et al., Guidelines for cardiac monitoring of children during and after anthracycline therapy: report of the Cardiology Committee of the Childrens Cancer Study Group. Pediatrics 1992; 89 (5 pt 1): 942-949.
52. Guarneri V, Lenihan DJ, Valero V, et al., Long-term cardiac tolerability of trastuzumab in metastatic breast cancer: the M.D. Anderson Cancer Center experience. J Clin Oncol 2006; 24: 4107-4115.
53. Cardinale D, Sandri MT, Colombo A, et al., Prognostic value of troponin I in cardiac risk stratification of cancer patients undergoing high-dose chemotherapy. Circulation 2004; 109: 2749-2754.
54. Nousiainen T, Vanninen E, Jantunen E, et al., Natriuretic peptides during the development of doxorubicin-induced left ventricular diastolic dysfunction. J Intern Med 2002; 251: 228-234.
55. Cardinale D, Colombo A, Sandri MT, et al., Prevention of high-dose chemotherapy-induced cardiotoxicity in high-risk patients by angiotensin-converting enzyme inhibition. Circulation 2006; 114: 2474-2481.
56. Kalay N, Basar E, Ozdogru I, et al., Protective effects of carvedilol against anthracycline-induced cardiomyopathy. J Am Coll Cardiol 2006; 48: 2258-2262.
57. Nakamae H, Tsumura K, Terada Y, et al., Notable effects of angiotensin II receptor blocker, valsartan, on acute cardiotoxic changes after standard chemotherapy with cyclophosphamide, doxorubicin, vincristine, and prednisolone. Cancer 2005; 104: 2492-2498.
58. De Angelis A, Piegari E, Cappetta D, et al., Anthracycline cardiomyopathy is mediated by depletion of the cardiac stem cell pool and is rescued by restoration of progenitor cell function. Circulation 2010; 121: 276-292.